Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2014
08/26/2014CA2800428C Treatment of type 2 diabetes
08/26/2014CA2780821C Mmp-13 inhibitors for the treatment of periodontitsis
08/26/2014CA2765852C Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections
08/26/2014CA2729819C Unit dosage of apadenoson
08/26/2014CA2656618C Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
08/26/2014CA2642414C Rapid release irbesartan-containing pharmaceutical composition
08/26/2014CA2630655C Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
08/26/2014CA2611443C Novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain
08/26/2014CA2604686C (1, 10b-dihydro-2-(aminoalkyl- phenyl)-5h-pyraz0l0 [1,5-c] [1,3] benz0xazin-5-yl) phenyl methanone derivatives as hiv viral repliation inhibitors
08/26/2014CA2585363C Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
08/26/2014CA2584295C Spiro-2, 4-pyrimidinediamine compounds and their uses
08/26/2014CA2574990C Antimicrobial copolymers and uses thereof
08/26/2014CA2476755C Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
08/26/2014CA2467309C Type iii secretion pathway in aeromonas salmonicida, and uses therefor
08/26/2014CA2390344C 85kda neisserial antigen
08/21/2014WO2014127378A2 Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
08/21/2014WO2014127360A1 Pcl compounds, compositions, and methods of use thereof
08/21/2014WO2014127351A2 Compositions and methods to alter gut microbial fermentation using sulfate-reducing bacteria
08/21/2014WO2014127335A1 Therapeutic compounds and uses thereof
08/21/2014WO2014127331A1 Novel uses
08/21/2014WO2014127315A1 Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
08/21/2014WO2014127256A1 Kappa opioid receptor selective compounds
08/21/2014WO2014127245A1 Treatment of klebsiella pneumoniae with liposomally formulated glutathione
08/21/2014WO2014127214A1 Therapeutic compounds and uses thereof
08/21/2014WO2014127201A1 Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors
08/21/2014WO2014127164A1 Substituted dihydropyrazoles as sphingosine receptor modulators
08/21/2014WO2014127152A1 Substituted pyrazole azetidines as sphingosine receptor modulators
08/21/2014WO2014127149A1 Substituted 4,5-dihydropyrazole-1,2,4-oxadiazole derivatives as sphingosine receptor modulators
08/21/2014WO2014127141A1 Substituted 1h-pyrazol-1,2,4-oxadiazole derivatives as sphingosine receptor modulators
08/21/2014WO2014127139A1 Treatment of multiple sclerosis with laquinimod
08/21/2014WO2014127116A1 Topical ocular analgesic agents
08/21/2014WO2014127066A1 Probiotic arginolytic oral compositions and methods of making and using probiotic arginolytic oral compositions
08/21/2014WO2014127052A1 Perfluoro-tert-butyl hydroxyproline
08/21/2014WO2014127042A1 Hydantoins that modulate bace-mediated app processing
08/21/2014WO2014127033A1 Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
08/21/2014WO2014127020A1 Epinephrine formulations for medicinal products
08/21/2014WO2014127018A1 Epinephrine formulations for medicinal products
08/21/2014WO2014127016A2 Ultrapure tetrahydrocannabinol-11-oic acids
08/21/2014WO2014127015A1 Epinephrine formulations for medicinal products
08/21/2014WO2014126979A1 Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
08/21/2014WO2014126972A1 Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
08/21/2014WO2014126969A1 Solid dispersions of low-water solubility actives
08/21/2014WO2014126944A2 Inhibitors of the renal outer medullary potassium channel
08/21/2014WO2014126885A1 Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
08/21/2014WO2014126802A1 Alkene azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
08/21/2014WO2014126728A1 Cosmetic compositions for deeper ethnic skin tones
08/21/2014WO2014126647A1 Photocatalytic degradation of sugar
08/21/2014WO2014126596A1 Neuroprotective multifunctional antioxidants and their monofunctional analogs
08/21/2014WO2014126594A1 Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
08/21/2014WO2014126580A1 Pesticidal compositions and processes related thereto
08/21/2014WO2014126541A1 Pharmaceutical compositions used in treating bacterial infections
08/21/2014WO2014126454A1 A process for producing high oleic content liquid palm oil fraction
08/21/2014WO2014126370A1 Film-forming pharmaceutical composition for wound healing and method for preparing the same
08/21/2014WO2014126267A1 Difluprednate emulsion composition containing antimicrobial metal
08/21/2014WO2014126266A1 Difluprednate emulsion composition containing zinc
08/21/2014WO2014125506A2 A process for the preparation of ivacaftor and its intermediates
08/21/2014WO2014125504A2 Pharmaceutical compositions of febuxostat
08/21/2014WO2014125444A1 Heterocyclic amides as kinase inhibitors
08/21/2014WO2014125443A1 Means and methods for assessing the quality of a biological sample
08/21/2014WO2014125426A1 Trisubstituted heterocyclic derivatives as ror gamma modulators
08/21/2014WO2014125413A1 Ip receptor agonist heterocyclic compounds
08/21/2014WO2014125408A2 Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
08/21/2014WO2014125397A1 SUBSTITUTED PHENYL HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
08/21/2014WO2014125394A1 HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
08/21/2014WO2014125352A1 Pharmaceutical compositions comprising tadalafil
08/21/2014WO2014125340A1 Smoke liquid for atomizers and/or vaporizers
08/21/2014WO2014125277A1 Method of producing microparticles
08/21/2014WO2014125276A1 Stem cell microparticles and mirna
08/21/2014WO2014125270A1 Process for preparing atazanavir sulphate
08/21/2014WO2014125124A1 Solid pharmaceutical dosage form of dolutegravir
08/21/2014WO2014125121A1 Compounds and compositions for treating neurodegenerative diseases
08/21/2014WO2014125085A1 Oral pharmaceutical formulations comprising nimesulide and thiocolchicoside
08/21/2014WO2014125084A1 Hydroxyindalpine derivatives and their medical use
08/21/2014WO2014125075A1 Albicidin derivatives, their use and synthesis
08/21/2014WO2014125052A1 Pharmaceutical composition for oral administration comprising fexofenadine and process for preparing thereof
08/21/2014WO2014125013A1 D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response
08/21/2014WO2014124981A1 Chewable composition for oral administration and process for preparing thereof
08/21/2014WO2014124978A2 Helicase-primase inhibitors for use in a method of treating alzheimer's disease
08/21/2014WO2014124862A1 Pharmaceutical compositions containing dexketoprofen and tramadol
08/21/2014WO2014124860A1 Specific pde4b-inhibitors for the treatment of diabetes mellitus
08/21/2014WO2014124757A1 Pyrrolotriazine derivatives as pi3k inhibitors
08/21/2014WO2014124651A1 Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
08/21/2014WO2014124560A1 Mglur regulators
08/21/2014WO2014124523A1 A method of treating obesity
08/21/2014WO2014124504A1 Compositions and methods for treating biofilms
08/21/2014WO2014124487A1 Ligand binding molecules and uses thereof
08/21/2014WO2014107730A3 Use of fatty acid niacin conjugates for treating diseases
08/21/2014WO2014102778A3 Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
08/21/2014WO2014102755A4 Bortezomib formulations
08/21/2014WO2014100815A3 Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof
08/21/2014WO2014100620A3 Compounds and methods for kinase modulation, and indications therefor
08/21/2014WO2014100071A3 Substituted pyrrolopyrimidines as hdm2 inhibitors
08/21/2014WO2014096388A3 Novel benzimidazole derivatives as kinase inhibitors
08/21/2014WO2014091388A3 Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
08/21/2014WO2014091298A3 Nitrogen containing morphinan derivatives and the use thereof
08/21/2014WO2014087298A4 Novel selective androgen receptor modulators
08/21/2014WO2014087231A3 Pharmaceutical composition having a neuroprotective, nootropic, antiamnesic effect, and method for preventing and/or treating states associated with cerebral circulation disorders, cerebrovascular and neurodegenerative diseases
08/21/2014WO2014083567A8 Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
08/21/2014WO2014078180A3 Coated devices for the administration of autologous biological molecules and for the isolation and elution of proteins from plasma
08/21/2014WO2014066799A3 Modulators of resistant androgen receptor
1 ... 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 ... 7860